Position in ERAS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$28,687,526
+$24,806,576 QoQ
Shares Held
1,565,913
+552.8% QoQ
Ownership
0.448%
of shares outstanding
% of Portfolio
4.95%
of 13F equity value
Holder Rank
#35
of 257 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 86%
Shared 0%
None 14%
Common Shares in ERAS Over Time
Shares Held
Position Value (USD)
Derivatives in ERAS
reported options exposure · as of Jun 30, 2026CallValue
$0
CallShares
0
PutValue
$90,000
PutShares
200,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026STEMPOINT CAPITAL LP holds $524,439,182 across 65 Biotechnology names. ERAS ranks #4 (5.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TNGX |
Tango Therapeutics, Inc.
|
1,223,019 | $38,231,573 | |
| 2 | ABVX |
Abivax S.A.
|
283,657 | $37,800,131 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
159,943 | $29,954,125 | |
| 4 | ERAS |
Erasca, Inc.
This page
|
1,565,913 | $28,687,526 | |
| 5 | TYRA |
Tyra Biosciences, Inc.
|
632,754 | $20,210,162 | |
| 6 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
200,851 | $19,578,955 | |
| 7 | ELVN |
Enliven Therapeutics, Inc.
|
346,914 | $17,605,885 | |
| 8 | MLYS |
Mineralys Therapeutics, Inc.
|
602,686 | $16,260,468 |
All Filings in ERAS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $90,000 | 200,000 | Put | Sole | 2026-08-14 | |
| 2026-06-30 | $28,687,526 | 1,565,913 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $3,880,950 | 239,861 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||